Diagnosis and Management of Hypertension Integrating General Medicine, Public Health, Nursing, and Radiology
DOI:
https://doi.org/10.22399/ijcesen.4046Keywords:
Hypertension, Diagnosis, Management, General Medicine, Public Health, Nursing, Radiology, Blood PressureAbstract
Hypertension, a prevalent and significant public health concern, necessitates a comprehensive approach to diagnosis and management that incorporates the expertise of general medicine, public health, nursing, and radiology. General practitioners play a pivotal role in identifying and diagnosing hypertension through regular health screenings and patient assessments. Accurate measurement of blood pressure, alongside a thorough evaluation of patient history and risk factors, is essential for effective diagnosis. Public health initiatives also contribute significantly by promoting awareness and preventative measures to mitigate hypertension's risk factors within communities. Campaigns focusing on lifestyle modifications—such as dietary changes, physical activity, and smoking cessation—are integral components of population-level strategies aimed at reducing the incidence of hypertension and its associated complications. The management of hypertension is further enhanced through a multidisciplinary approach that includes nursing care, patient education, and radiological assessments. Nurses are critical for monitoring patients, reinforcing lifestyle modifications, and ensuring adherence to prescribed treatment plans. They frequently serve as the frontline in patient education, providing vital information regarding medication adherence and the importance of regular follow-up. Additionally, radiological tools, such as echocardiograms or imaging tests, can help assess organ damage caused by chronic hypertension, guiding treatment decisions. This integrated approach allows for tailored management strategies that address individual patient needs while addressing broader public health goals, ultimately aiming for improved outcomes and reduced morbidity associated with hypertension.
References
[1] Messerli F.H., Bangalore S. Treatment-resistant hypertension: another Cinderella story. Eur. Heart J. 2013;34:1175–1177.
[2] SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N. Engl. J. Med. 2015;373:2103–2116.
[3] Kong P., Christia P., Frangogiannis N.G. The pathogenesis of cardiac fibrosis. Cell. Mol. Life Sci. 2014;71:549–574.
[4] Mancia G., Kreutz R., Brunstr M., Burnier M., Grassi G., Januszewicz A., Lorenza Muiesan M., Tsioufis K., Agabiti-Rosei E., Abd Elhady Algharably E., et al. ESH Guidelines. 2023.
[5] Zhan Q., Peng W., Wang S., Gao J. Heart Failure with Preserved Ejection Fraction: Pathogenesis, Diagnosis, Exercise, and Medical Therapies. J. Cardiovasc. Transl. Res. 2023;16:310–326.
[6] McEvoy J.W., McCarthy C.P., Bruno R.M., Brouwers S., Canvan M., Ceconi C., Christodorescu R., Daskalopoulou S., Ferro C., Gerdts E., et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur. Heart J. 2024. Epub ahead of print.
[7] Borovac J.A., D’Amario D., Bozic J., Glavas D. Sympathetic nervous system activation and heart failure: current state of evidence and the pathophysiology in the light of novel biomarkers. World J. Cardiol. 2020;12:373–408.
[8] Verdecchia P., Angeli F., Reboldi G. Hypertension and atrial fibrillation: Doubts and certainties from basic and clinical studies. Circ. Res. 2018;122:352–368.
[9] Nagueh S.F. Left Ventricular Diastolic Function: Understanding Pathophysiology, Diagnosis, and Prognosis With Echocardiography. JACC Cardiovasc. Imaging. 2020;13:228–244.
[10] Whelton P.K., Carey R.M., Mancia G., Kreutz R., Bundy J. Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparisons, Reflections, and Recommendations. Circulation. 2022;146:868–877.
[11] Reinier K., Dervan C., Singh T., Uy-Evanado A., Lai S., Gunson K., Jui J., Chugh S. Increased left ventricular mass and decreased left ventricular systolic function have independent pathways to ventricular arrhythmogenesis in coronary artery disease. Heart Rhythm. 2011;8:1177–1182.
[12] Hartupee J., Mann D.L. Neurohormonal activation in heart failure with reduced ejection fraction. Nat. Rev. Cardiol. 2016;14:30–38.
[13] Grewal J., McKelvie R., Lonn E., Tait P., Carlsson J., Gianni M., Jarnert C., Persson H. BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction. Eur. J. Heart Fail. 2008;10:252–259.
[14] Aronow W.S. Hypertension associated with atrial fibrillation. Ann. Transl. Med. 2017;5:457.
[15] Carey R.M., Calhoun D.A., Bakris G.L., Brook R., Daugherty S., Dennison-Himmelfarb C., Egan B., Flack J., Gidding S., Judd E., et al. Resistant hypertension: Detection, evaluation, and management a scientific statement from the American Heart Association. Hypertension. 2018;72:E53–E90.
[16] Vaidya K., Semsarian C., Chan K.H. Atrial Fibrillation in Hypertrophic Cardiomyopathy. Heart Lung Circ. 2017;26:975–982.
[17] Martin T.G., Juarros M.A., Leinwand L.A. Regression of cardiac hypertrophy in health and disease: Mechanisms and therapeutic potential. Nat. Rev. Cardiol. 2023;20:347–363.
[18] Bing R., Dweck M.R. Myocardial fibrosis: Why image, how to image and clinical implications. Heart. 2019;105:1832–1840.
[19] Karamitsos T.D., Arvanitaki A., Karvounis H., Neubauer S., Ferreira V. Myocardial Tissue Characterization and Fibrosis by Imaging. JACC: Cardiovasc. Imaging. 2020;13:1221–1234.
[20] Hagi K., Kochi K., Watada H., Haku K., Ueki K. Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of two randomized, placebo-controlled trials. J. Diabetes Investig. 2023;14:1101–1109.
[21] Humphrey J.D. Mechanisms of vascular remodeling in hypertension. Am. J. Hypertens. 2021;34:432–441.
[22] Haider A.W., Larson M.G., Benjamin E.J., Levy D. Increased Left Ventricular Mass and Hypertrophy Are Associated With Increased Risk for Sudden Death. J. Am. Coll. Cardiol. 1998;32:1454–1459.
[23] Chirinos J.A., Segers P., Hughes T., Townsend R. Large-Artery Stiffness in Health and Disease: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2019;74:1237–1263.
[24] Lawson C.A., Zaccardi F., Squire I., Okhai H., Davies M., Huang W., Mamas M., Lam C.S., Khunti K., Kadam U.T. Risk Factors for Heart Failure: 20-Year Population-Based Trends by Sex, Socioeconomic Status, and Ethnicity. Circ. Heart Fail. 2020;13:E006472.
[25] Levine G.N., Al-Khatib S.M., Beckman J.A., Birtcher K., Bozkurt B., Brindis R., Cigarroa J., Curtis L., Deswal A., Fleisher L., et al. Force on Clinical Practice Guidelines. Hypertension. 2018;71:13–115.
[26] Masenga S.K., Kirabo A. Hypertensive heart disease: Risk factors, complications and mechanisms. Front. Cardiovasc. Med. 2023;10:1205475.
[27] Gallo G., Volpe M., Savoia C. Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications. Front. Med. 2022;8:798958.
[28] Williams B., Mancia G., Spiering W., Rosei E., Azizi M., Burnier M., Clement D., Coca A., De Simone G., Dominiczak A., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 2018;39:3021–3104.
[29] Messerli F.H., Rimoldi S.F., Bangalore S. Mini-Focus Issue: Cardiovascular Comorbidities The Transition From Hypertension to Heart Failure Contemporary Update. 2017.
[30] Trivedi S.J., Altman M., Stanton T., Thomas L. Echocardiographic Strain in Clinical Practice. Heart Lung Circ. 2019;28:1320–1330.
[31] Maron M.S., Maron B.J., Harrigan C., Buros J., Gibson C., Olivotto I., Biller L., Lesser J., Udelson J., Manning W., et al. Hypertrophic Cardiomyopathy Phenotype Revisited After 50 Years With Cardiovascular Magnetic Resonance. J. Am. Coll. Cardiol. 2009;54:220–228.
[32] Ames M.K., Atkins C.E., Pitt B. The renin-angiotensin-aldosterone system and its suppression. J. Vet. Intern. Med. 2019;33:363–382.
[33] Bayram N., Akoğlu H., Sanri E., Karacabey S., Efeoglu M., Onur O., Denizbasi A. Diagnostic Accuracy of the Electrocardiography Criteria for Left Ventricular Hypertrophy (Cornell Voltage Criteria, Sokolow-Lyon Index, Romhilt-Estes, and Peguero-Lo Presti Criteria) Compared to Transthoracic Echocardiography. Cureus. 2021;14:e13883.
[34] Lorell B.H., Carabello B.A. Left Ventricular Hypertrophy Pathogenesis, Detection, and Prognosis. 2000.
[35] Ettehad D., Emdin C.A., Kiran A., Anderson S., Callender T., Emberson J., Chalmers J., Rodgers A., Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet. 2016;387:957–967.
[36] Bunda S., Liu P., Wang Y., Hinek A. Aldosterone induces elastin production in cardiac fibroblasts through activation of insulin-like growth factor-I receptors in a mineralocorticoid receptor-independent manner. Am. J. Pathol. 2007;171:809–819.
[37] Zhang W., Zhang S., Deng Y., Wu S., Ren J., Sun G., Yang J., Jiang Y., Xu X., Wang T., et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. New Engl. J. Med. 2021;385:1268–1279.
[38] Campbell-Quintero S., Echeverría L.E., Gómez-Mesa J.E., Rivera-Toquica A., Renteria-Asprilla C., Lopez-Garzon N., Alcala-Hernandez A., Accini-Mendoza J., BAquero-Lozano G., Martinez-Carvajal A., et al. Comorbidity profile and outcomes in patients with chronic heart failure in a Latin American country: Insights from the Colombian heart failure registry (RECOLFACA) Int. J. Cardiol. 2023;378:123–129.
[39] Ekström M., Hellman A., Hasselström J., Hage C., Kahan T., Ugander M., Wallén H., Persson H., Linde C. The transition from hypertension to hypertensive heart disease and heart failure: The PREFERS Hypertension study. ESC Heart Fail. 2020;7:737–746.
[40] Pisano A., Iannone L.F., Leo A. Russo, E.; Coppolino, G.; Bilignano, D. Renal denervation for resistant hypertension. Cochrane Database Syst. Rev. 2021;11:CD011499.
[41] Roumie C.L., Hung A.M., Russell G.B., Basile J., Kreider K., Nord J., Ramsey T., Rastogi A., Sweeney M., Tamariz L. Blood Pressure Control and the Association with Diabetes Mellitus Incidence: Results from SPRINT Randomized Trial. Hypertension. 2020;75:331–338.
[42] Sayin B.Y., Oto A. Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options. Cardiol. Ther. 2022;11:203–230.
[43] Jenkins S., Cross A., Osman H., Salim F., Lane D., Bernieh D., Khunti K., Gupta P. Effectiveness of biofeedback on blood pressure in patients with hypertension: Systematic review and meta-analysis. J. Hum. Hypertens. 2024;38:719–727.
[44] Papademetriou V., Zaheer M., Doumas M., Lovato L., Applegate W., Tsioufis C., Mottle A., Punthakee Z., Cushman M. Cardiovascular outcomes in action to control cardiovascular risk in diabetes: Impact of blood pressure level and presence of kidney disease. Am. J. Nephrol. 2016;43:271–280.
[45] Saheera S., Krishnamurthy P. Cardiovascular Changes Associated with Hypertensive Heart Disease and Aging. Cell Transplant. 2020;29:0963689720920830.
[46] Tokgozoglu L., Torp-Pedersen C. Redefining cardiovascular risk prediction: Is the crystal ball clearer now? Eur. Heart J. 2021;42:2468–2471.
[47] Goff D.C., Lloyd-Jones D.M., Bennett G., Coady S., D’Agostino R., Gibbons R., Greenland P., Lackland D., Levy D., O’Donnell C., et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;129:S49–S73.
[48] Miró Ò., Conde-Martel A., Llorens P., Salamanca-Bautista P., Gil V., González-Franco Á., Jacob J., Casado J., Tost J., Montero-Perez-Barquero M., et al. The influence of comorbidities on the prognosis after an acute heart failure decompensation and differences according to ejection fraction: Results from the EAHFE and RICA registries. Eur. J. Intern. Med. 2023;111:97–104.
[49] Liang M., Bian B., Yang Q. Characteristics and long-term prognosis of patients with reduced, mid-range, and preserved ejection fraction: A systemic review and meta-analysis. Clin. Cardiol. 2022;45:5–17.
[50] Izraiq M., Alawaisheh R., Ibdah R., Dabbas A., Ahmed Y., Mughrabi Sabbagh A., Zuriak A., Ababneh M., Toubasi A., Al-Bkoor B. Machine Learning-Based Mortality Prediction in Chronic Kidney Disease among Heart Failure Patients: Insights and Outcomes from the Jordanian Heart Failure Registry. Medicina (Lithuania) 2024;60:831.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 International Journal of Computational and Experimental Science and Engineering
This work is licensed under a Creative Commons Attribution 4.0 International License.
